Myriad Genetics, Inc. MYGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.62% | -26.69% | -331.65% | 71.17% | 91.71% |
| Total Depreciation and Amortization | 0.80% | 0.00% | -0.79% | 0.00% | -10.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 24.44% | -36.17% | 88.00% | -48.28% | -95.60% |
| Change in Net Operating Assets | 1.49% | 263.41% | -412.50% | -107.48% | 179.26% |
| Cash from Operations | 21.69% | 47.13% | -248.11% | -49.76% | 255.15% |
| Capital Expenditure | 14.29% | 61.11% | -14.89% | -67.86% | 0.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 72.73% | 0.00% | 15.38% | 61.76% | 17.07% |
| Cash from Investing | 34.38% | 50.77% | -8.33% | 3.23% | 10.14% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | 50.00% | -100.00% | -133.33% | 100.50% | -60,000.00% |
| Issuance of Common Stock | -100.00% | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | 50.00% | 86.21% | -141.67% | -300.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 5.95% | -- |
| Cash from Financing | -113.64% | 173.33% | 63.41% | -114.59% | 2,061.54% |
| Foreign Exchange rate Adjustments | -200.00% | 200.00% | -200.00% | -- | -100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.17% | 63.64% | -622.86% | -104.92% | 510.98% |